BUND FINANCE

BUND FINANCE › Stocks › BIIB

Biogen Inc. (BIIB)

NASDAQ · Stock price, chart and technical analysis

US$251.41+0.6200 (+0.25%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$250.79
OpenUS$248.56
Day rangeUS$247.00 – US$252.79
52-week rangeUS$160.36 – US$261.00
Market capUS$37.16B
Volume1.14M
50-day averageUS$234.73
200-day averageUS$205.87
Beta0.17

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$11.0BUS$10.2BUS$9.8BUS$9.7BUS$9.9B
Net incomeUS$1.6BUS$3.0BUS$1.2BUS$1.6BUS$1.3B
EPS (diluted)10.4020.877.9711.198.79
Gross margin80.8%77.6%74.2%76.1%75.7%
Operating margin25.4%28.4%21.3%25.7%25.0%
Net margin14.2%30.0%11.8%16.9%13.1%
Free cash flowUS$3.4BUS$1.1BUS$1.2BUS$2.5BUS$2.1B
Total debtUS$7.6BUS$6.6BUS$7.3BUS$6.6BUS$6.9B
CashUS$2.3BUS$3.4BUS$1.0BUS$2.4BUS$3.0B

Compound annual growth: revenue -2.6% · net income -4.5% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E107.4x20.4x27.1x
EV / EBITDA30.1x12.3x16.5x
Operating margin7.6%—3.6%
Net margin3.4%—-0.0%
Debt / equity0.69—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Biogen Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEOChristopher A. Viehbacher
Employees7,500
IPO date1991-09-17

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an …

www.biogen.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice